Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Abstract

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).

Keywords

Affiliated Institutions

• Cleveland Clinic US
• University of Louisville US
• NYU Langone’s Laura and Isaac Perlmutter Cancer Center
• Prisma Health US
• Bristol-Myers Squibb (United States) US
• Huntsman Cancer Institute US
• University of New Mexico US
• Université Paris-Sud FR
• Institut Gustave Roussy FR
• Hadassah Medical Center IL
• Dana-Farber Cancer Institute US
• New York University US
• Cornell University US
• St. Luke's University Health Network US
• Oregon Health & Science University US
• Duke University US
• Memorial Sloan Kettering Cancer Center US
• Washington University in St. Louis US
• Northern California Melanoma Center US

Related Publications